Kari M A, Raivio K O, Stenman U H, Voutilainen R
Children's Hospital, University of Helsinki, Finland.
Pediatr Res. 1996 Aug;40(2):319-24. doi: 10.1203/00006450-199608000-00021.
Our aim was to assess adrenocortical function in very low birth weight infants, specifically to evaluate the impact of gestational age and dexamethasone (DEX) therapy on serum concentrations of total and free cortisol, dehydroepiandrosterone sulfate (DHEAS), and steroid-binding globulins. Twelve moderately preterm or full-term neonates of 38 +/- 4 (mean +/- SD) wk of gestation and 36 ill preterm neonates of 26 +/- 2 (mean +/- SD) wk of gestation were studied. Twenty-three of the 36 ill preterm neonates participated in a randomized neonatal DEX trial for the treatment of early chronic lung disease and received a 1-wk treatment of DEX or placebo. Serum concentrations of cortisol, corticosteroid-binding globulin (CBG), sex hormone-binding globulin (SHBG), and DHEAS were measured, and an ACTH test was performed. Gestational age correlated with the umbilical cord concentrations of total cortisol (r = 0.702, p < 0.01), free cortisol (r = 0.489, p < 0.05), DHEAS (r = 0.608, p < 0.01), and SHBG (r = 0.831, p < 0.01), but not significantly with the concentration of CBG (r = 0.428, p = 0.076). One-week DEX therapy decreased the serum concentrations of CBG (DEX 295 nmol/L, placebo 504 nmol/L; p < 0.01), DHEAS (DEX 6.5 mumol/L, placebo 11.8 mumol/L; p < 0.05), and the basal (DEX 81 nmol/L, placebo 176 nmol/L; p < 0.01) and ACTH-stimulated cortisol levels (DEX 458 nmol/L, placebo 817 nmol/L; p < 0.05). One week after discontinuation of DEX or placebo, basal cortisol concentrations did not differ significantly, but ACTH-stimulated cortisol levels were lower in the DEX-treated than in the placebo-treated infants. DEX therapy decreased the serum CBG and DHEAS concentrations and caused a transient suppression in the adrenocortical function. Despite severe illness, the very preterm neonates had relatively low basal cortisol concentrations, suggesting their reduced ability to respond adequately to stress during intensive care.
我们的目的是评估极低出生体重儿的肾上腺皮质功能,特别是评估胎龄和地塞米松(DEX)治疗对总皮质醇和游离皮质醇、硫酸脱氢表雄酮(DHEAS)及类固醇结合球蛋白血清浓度的影响。研究了12名孕龄38±4(均值±标准差)周的中度早产或足月儿以及36名孕龄26±2(均值±标准差)周的患病早产儿。36名患病早产儿中的23名参与了一项用于治疗早期慢性肺病的新生儿DEX随机试验,接受了为期1周的DEX或安慰剂治疗。检测了皮质醇、皮质类固醇结合球蛋白(CBG)、性激素结合球蛋白(SHBG)和DHEAS的血清浓度,并进行了促肾上腺皮质激素(ACTH)试验。胎龄与脐带血总皮质醇浓度(r = 0.702,p < 0.01)、游离皮质醇浓度(r = 0.489,p < 0.05)、DHEAS浓度(r = 0.608,p < 0.01)和SHBG浓度(r = 0.831,p < 0.01)相关,但与CBG浓度无显著相关性(r = 0.428,p = 0.076)。为期1周的DEX治疗降低了CBG的血清浓度(DEX组295 nmol/L,安慰剂组504 nmol/L;p < 0.01)、DHEAS的血清浓度(DEX组6.5 μmol/L,安慰剂组11.8 μmol/L;p < 0.05)以及基础皮质醇水平(DEX组81 nmol/L,安慰剂组176 nmol/L;p < 0.01)和ACTH刺激后的皮质醇水平(DEX组458 nmol/L,安慰剂组817 nmol/L;p < 0.05)。停用DEX或安慰剂1周后,基础皮质醇浓度无显著差异,但DEX治疗组婴儿ACTH刺激后的皮质醇水平低于安慰剂治疗组。DEX治疗降低了血清CBG和DHEAS浓度,并导致肾上腺皮质功能短暂抑制。尽管病情严重,但极早产儿的基础皮质醇浓度相对较低,这表明他们在重症监护期间对应激的充分反应能力降低。